BIMATOPROST相关论文
Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle gla
...
1 996年适利达应用于临床 ,是美国FDA批准应用于临床的第一个局部前列腺素类抗青光眼药物。目前适利达 (Latanoprost)在欧美等发达......
Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle gla
...
目的：比较市售药物Bimatoprost或travoprost加上拉坦前列腺紊治疗激光诱导的单侧猴青光眼的降眼压疗效。......
IOP LOWERING EFFICACY OF BIMATO－PROST IN GLAUCOMA AND OCULAR HYPERTENSION PATIENTS NON－RESPONSIVE TO
<正> Purpose: To determine if bimatoprost is effective in patients who are non-responsive to latanoprost Methods: Open-l......
目的：比较bimatoprost和马来酸噻吗心安治疗青光眼和高眼压症。...
<正> Bimatoprost is a novel ocular hypotensive agent and a synthetic prostamide analog. Pharmacological evaluation, invo......
DIFFERENTIAL RESPONSES TO BIMATO－PROST AND PGF2ALPHA IN C AT IRIS SPHINCTER CLLS SUGGEST THE INVOLVE
<正> Bimatoprost (LUMIGAN) is a novel synthetic prostamide that potently lowers intraocular pressure in dogs, primates a......
<正> Lumigan (Bimatoprost) is a synthetic prostamide analog with a pharmacology profile that is distinct from prostaglan......
期刊
<正> Purpose: To evaluate the efficacy and safety of bimatoprost 0.03 percent given every evening versus timolol maleate......
<正> Objective: To investigate the effects of topical travoprost 0.004% and topical bimatoprost 0.03% on retrobulbar blo......
期刊
CLINICAL AND ECONOMIC OUTCOMES OF LATANOPROST BIMATOPROST OR TRAVOPROST THERAPY IN GLAUCOMA PATIENTS
<正> Purpose: To evaluate rates of hyperemia in patients treated with latanoprost, bimatoprost, or travoprost and to com......
<正> Purpose: Bimatoprost 0,03% is a prostamide with a good efficacy like an ocular hypotensive agent. A collateral effe......
<正> Purpose: To compare the intraocular pressure (IOP)-lowering efficacy of topically administered bimatoprost 0.03% wi......
<正> Objective: To compare the long-term efficacy and safety of bi-matoprost vs timolol in glaucoma/ocular hypertensive ......
A FOUR－WEEK COMPARISON OF BIMATOPROST 0.03% AND BIMATOPROST 0.015% IN PATIENTS WITH ELEVATED INTRAOC
<正> Purpose: Intraocular Pressure (IOP) control is the main goal in glaucoma treatment However, despite satisfactory co......
期刊
COMPARISON OF THE IOP－LOWEREING EFFICACY OF BIMATOPROST 0.03% AND TRAVOPROST 0.004% IN PATIENTS WITH
<正> Purpose: To evaluate the IOP-lowering efficacy of bimatoprost and travoprost for the treatment of glaucoma and ocul......
AN EVALUATION OF BIMATIOPROST MONOTHERAPY IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION PREVIOUSL
<正> Objective: To evaluate the safety and efficacy of bimatoprost 0.03% (Lumigan) monotherapy in patients with glaucoma......
<正> Purpose: To compare the effect of bimatoprost, latanoprost, travoprost and unoprostone on intraocular pressure and ......
<正> Objective: To compare efficacy and safety of bimato-prost (Lumigan) QD vs timolol/dorzolamide (Cosopt) BID. Methods......
EFFICACY AND SAFETY OF BIMATOPROST IN PATIENTS WITH UNCON－TROLLED GLAUCOMA ON MAXIMAL TOLERABLE MEDI
<正> Purpose: to evaluate the efficacy and safety of bimatoprost as alternative to filtration surgery in patients with u......
期刊
目的：评估拉坦前列素，曲伏前列素和比马前列素在挪威，瑞典及丹麦（斯堪的纳维亚）治疗开角型青光眼的成本效用。方法：建立马尔可夫卫生经济......
目的研究前列腺素类似物的新成员Bimatoprost的降眼压作用，并评价其安全性。方法对正常无色素兔的一只眼滴入Bimatoprost，另一只眼滴......
<正> Purpose: To evaluate the pressure lowering effects of bimato-prost once daily at bedtime in patients who failed pre......
一、简介 商品名：Lumigan(美)Allergan公司研制，于2001年3月首次在美国上市。...
意大利研究者指出，使用bimatoprost（Ⅰ）治疗青光眼四年以上与以滤光手术作为初始治疗相比，似乎更经济。......
1996年适利达应用于临床,是美国FDA批准应用于临床的第一个局部前列腺素类抗青光眼药物.目前适利达(Latanoprost)在欧美等发达国家......
Purpose: This is a retrospective, comparative, head-to-head, not commissioned study about the efficacy of bimato-prost 0......
Objectives: To compare ocular surface changes induced via glaucoma treatment in patients using fixed combinations of bim......
据一多国研究小组称，在欧洲单药治疗青光眼患者时，与拉坦前列素（latanoprost）（Ⅱ）相比，bimatoprost（Ⅰ）更有效且花费较少。......
